[
  {
    "ts": null,
    "headline": "Eli Lilly (LLY): Assessing Valuation After Another Strong Share Price Run",
    "summary": "Why Eli Lilly Stock Keeps Pushing Higher Eli Lilly (LLY) has been grinding higher again, with shares up roughly 2% over the past week and more than 30% this year, as investors lean into its diabetes and obesity franchise. See our latest analysis for Eli Lilly. With the share price now around $1,027.51 and a powerful 90 day share price return of about 36%, momentum looks firmly intact and echoes Eli Lilly’s multi year total shareholder return that has hugely rewarded patient holders. If Eli...",
    "url": "https://finnhub.io/api/news?id=3c451d629cf7f14882edd9bd66c332cdd2a8e848fca803ae5e1d955d696a2f70",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765656552,
      "headline": "Eli Lilly (LLY): Assessing Valuation After Another Strong Share Price Run",
      "id": 137792092,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Why Eli Lilly Stock Keeps Pushing Higher Eli Lilly (LLY) has been grinding higher again, with shares up roughly 2% over the past week and more than 30% this year, as investors lean into its diabetes and obesity franchise. See our latest analysis for Eli Lilly. With the share price now around $1,027.51 and a powerful 90 day share price return of about 36%, momentum looks firmly intact and echoes Eli Lilly’s multi year total shareholder return that has hugely rewarded patient holders. If Eli...",
      "url": "https://finnhub.io/api/news?id=3c451d629cf7f14882edd9bd66c332cdd2a8e848fca803ae5e1d955d696a2f70"
    }
  },
  {
    "ts": null,
    "headline": "My Top 3 Healthcare Stocks to Buy in 2026",
    "summary": "These habitual market beaters can pull it off again.",
    "url": "https://finnhub.io/api/news?id=d10e614919cfb302e2bf095e946f09df3cd7f5ebc3b03804b7186c8a20c5b313",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765655820,
      "headline": "My Top 3 Healthcare Stocks to Buy in 2026",
      "id": 137792093,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "These habitual market beaters can pull it off again.",
      "url": "https://finnhub.io/api/news?id=d10e614919cfb302e2bf095e946f09df3cd7f5ebc3b03804b7186c8a20c5b313"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Leads Five Stocks Near Buy Points In Divided Market",
    "summary": "Eli Lilly, United Airlines and Urban Outfitters lead five stocks that are showing strength, near buy points, as AI stocks struggle.",
    "url": "https://finnhub.io/api/news?id=4b03fbc3481edf71a34b49e3174f3fac360a75b0c46f3024018d6293f77b5a03",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765630814,
      "headline": "Eli Lilly Leads Five Stocks Near Buy Points In Divided Market",
      "id": 137792094,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly, United Airlines and Urban Outfitters lead five stocks that are showing strength, near buy points, as AI stocks struggle.",
      "url": "https://finnhub.io/api/news?id=4b03fbc3481edf71a34b49e3174f3fac360a75b0c46f3024018d6293f77b5a03"
    }
  },
  {
    "ts": null,
    "headline": "Stock Market Week Ahead: A Catch-Up Week For Econ Data",
    "summary": "Micron and Nike are among the week's big earnings reports. But economic news may steal the show, as the flow of federal attempts to recover.",
    "url": "https://finnhub.io/api/news?id=cea8390a8c90be980bb209a28d32e22f0e1ea9482898d6d97d0c801e109110fe",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765629884,
      "headline": "Stock Market Week Ahead: A Catch-Up Week For Econ Data",
      "id": 137792095,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Micron and Nike are among the week's big earnings reports. But economic news may steal the show, as the flow of federal attempts to recover.",
      "url": "https://finnhub.io/api/news?id=cea8390a8c90be980bb209a28d32e22f0e1ea9482898d6d97d0c801e109110fe"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly: The Right Long-Term Strategy",
    "summary": "Eli Lilly's innovation and pipeline diversification support long-term growth, despite patent risks and competition. Read more on LLY stock here.",
    "url": "https://finnhub.io/api/news?id=7cbe803f884a8945aad6b83c6a9a2ce67e0afb8f38f6abe0065fab9acd887ad6",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765600404,
      "headline": "Eli Lilly: The Right Long-Term Strategy",
      "id": 137774561,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1874681159/image_1874681159.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Eli Lilly's innovation and pipeline diversification support long-term growth, despite patent risks and competition. Read more on LLY stock here.",
      "url": "https://finnhub.io/api/news?id=7cbe803f884a8945aad6b83c6a9a2ce67e0afb8f38f6abe0065fab9acd887ad6"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Further Cements Itself As The King Of Weight Loss",
    "summary": "Eli Lilly leads incretins via Zepbound/Mounjaro, retatrutide at 28.7% loss, $50B R&D and US buildout, 2025 guidance, valuation. Read why LLY stock is a hold.",
    "url": "https://finnhub.io/api/news?id=6723d87fb9664142353a4c230abcbeaafb16a748d8f6da4db64c4d08a4c4b518",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765596110,
      "headline": "Eli Lilly Further Cements Itself As The King Of Weight Loss",
      "id": 137774323,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1414474713/image_1414474713.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Eli Lilly leads incretins via Zepbound/Mounjaro, retatrutide at 28.7% loss, $50B R&D and US buildout, 2025 guidance, valuation. Read why LLY stock is a hold.",
      "url": "https://finnhub.io/api/news?id=6723d87fb9664142353a4c230abcbeaafb16a748d8f6da4db64c4d08a4c4b518"
    }
  }
]